Table 1 Patients’ characteristics according to LiverTox A drug administration.
Characteristic | N | No LiverTox A Drugs, N = 4,799 | At least One LiverTox A, N = 3,416 | N, overall = 8,215 | p-value |
|---|---|---|---|---|---|
Sex (Male) | 8,215 | 2,479 (52%) | 1,982 (58%) | 4,461 (54%) | < 0.001 |
Age | 8,215 | 81 (74, 87) | 81 (75, 85) | 81 (75, 86) | < 0.001 |
Geographic Area | 8,190 | ||||
North | 3,258 (68%) | 2,238 (66%) | 5,496 (67%) | ||
Centre | 1,111 (23%) | 764 (22%) | 1,875 (23%) | ||
South | 413 (8.6%) | 406 (12%) | 819 (10%) | ||
BMI | 8,160 | 26.0 (23.4, 29.0) | 26.7 (24.1, 29.8) | 26.3 (23.7, 29.4) | < 0.001 |
BMI ≥ 25 | 8,160 | 2,887 (61%) | 2,264 (66%) | 5,151 (63%) | < 0.001 |
Family history of Cardiovascular Disease | 6,904 | 339 (8.9%) | 306 (9.9%) | 645 (9.3%) | 0.154 |
Smoke | 7,378 | 528 (13%) | 506 (16%) | 1,034 (14%) | < 0.001 |
Alcohol consumption | 7,096 | 385 (9.8%) | 288 (9.1%) | 673 (9.5%) | 0.261 |
CHA₂DS₂-VASc | 8,215 | 3.0 (3.0, 4,0) | 4.0 (3.0, 5,0) | 4.0 (3.0, 5,0) | < 0.001 |
Hypertension | 8,215 | 3,593 (75%) | 2,946 (86%) | 6,539 (80%) | < 0.001 |
Diabetes | 8,215 | 700 (15%) | 927 (27%) | 1,627 (20%) | < 0.001 |
Previous cerebral vasculopathy | 8,215 | 644 (13%) | 666 (19%) | 1,310 (16%) | < 0.001 |
Ischemic heart disease | 8,215 | 357 (7.4%) | 1,022 (30%) | 1,379 (17%) | < 0.001 |
Cancer | 8,215 | 682 (14%) | 517 (15%) | 1,199 (15%) | 0.243 |
Chronic Respiratory Disease | 8,215 | 511 (11%) | 516 (15%) | 1,027 (13%) | < 0.001 |
Cirrhosis & varices | 7,609 | 35 (0.8%) | 20 (0.6%) | 55 (0.7%) | 0.265 |
Hypothyroidism | 7,127 | 331 (8.4%) | 297 (9.3%) | 628 (8.8%) | 0.169 |
Hyperthyroidism | 7,118 | 59 (1.5%) | 131 (4.1%) | 190 (2.7%) | < 0.001 |
Dementia | 7,446 | 157 (3.8%) | 76 (2.3%) | 233 (3.1%) | < 0.001 |
Platelets [× 109/L ] | 8,165 | 214 (180, 260) | 210 (175, 254) | 212 (177, 257) | 0.001 |
Creatinine clearance [mL/min] | 8,152 | 64 (48, 83) | 61 (46, 80) | 62 (47, 82) | < 0.001 |
Kidney Function Class | 8,152 | < 0.001 | |||
Normal (≥ 60) | 2,682 (56%) | 1,782 (52%) | 4,464 (55%) | ||
Decreased (30–59) | 1,858 (39%) | 1,422 (42%) | 3,280 (40%) | ||
Severely decreased (< 30) | 208 (4.4%) | 200 (5.9%) | 408 (5.0%) | ||
AST [U/L] | 6,241 | 20 (16, 26) | 20 (16, 26) | 20 (16, 26) | 0.450 |
AST increased (> 40 U/L) | 6,241 | 244 (7.1%) | 192 (6.8%) | 436 (7.0%) | 0.584 |
ALT [U/L] | 6,488 | 19 (14, 26) | 20 (15, 26) | 19 (14, 26) | 0.008 |
ALT increased (> 45 U/L) | 6,488 | 209 (5.8%) | 210 (7.2%) | 419 (6.5%) | 0.023 |
Either transaminasis increased | 6,608 | 341 (9.3%) | 297 (10%) | 638 (9.7%) | 0.348 |
FIB-4 | 6,117 | 1.78 (1.32, 2.41) | 1.80 (1.33, 2.40) | 1.79 (1.32, 2.40) | 0.865 |
High FIB-4 (> 3.25) | 6,117 | 356 (11%) | 245 (8.8%) | 601 (9.8%) | 0.019 |
